SCHEMBL3713073

SCHEMBL3713073

Fc1ccc(Br)c2ccncc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.60
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
IMPDH2 P12268 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
MAPK10 P53779 1/20 0.36
LOXL2 Q9Y4K0 1/20 0.35
IDO1 P14902 3/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ACHE P22303 1/20 0.34
EGFR P00533 1/20 0.34
CHUK O15111 2/20 0.33
EP300 Q09472 1/20 0.33
KAT2B Q92831 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29456309 1.00 AXL (0.60) AXLMEN1KMT2ARXFP1IMPDH2
SCHEMBL29751394 0.92 AXL (0.55) AXLIMPDH2MAPK8MAPK9MAPK10
SCHEMBL22787692 0.92 AXL (0.55) AXLIMPDH2MAPK8MAPK9MAPK10
SCHEMBL29890100 0.84 AXL (0.72) AXLMEN1KMT2ARXFP1IMPDH2
SCHEMBL244397 0.84 AXL (0.72) AXLMEN1KMT2ARXFP1IMPDH2
SCHEMBL246823 0.75 AXL (1.00) AXLMEN1KMT2AIMPDH2IDO1
SCHEMBL21917158 0.75 AXL (0.60) AXLMEN1KMT2ARXFP1IMPDH2
SCHEMBL1350740 0.75 AXL (0.55) AXLIMPDH2LOXL2IDO1MAPT
SCHEMBL30319516 0.75 AXL (1.00) AXLMEN1KMT2AIMPDH2IDO1
SCHEMBL12245721 0.75 AXL (0.60) AXLMEN1KMT2ARXFP1IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4055014-B1 PYRROLIDINE AND PIPERIDINE COMPOUNDS YUHAN CORP (KR) 2025-04-30 EP disclosed
WO-2025020886-A1 AZAQUINAZOLINE RING DERIVATIVE AND USE THEREOF 浙江星浩澎博医药有限公司 2025-01-30 WO disclosed
CN-114867719-B Pyrrolidine and piperidine compounds 柳韩洋行 2024-06-25 CN disclosed
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 SRX CARDIO, LLC (US) 2024-02-06 US disclosed
CN-110770211-B Alpha, beta unsaturated amide compound 协和麒麟株式会社 2023-09-19 CN disclosed
US-11655235-B2 Pyrrolidine and piperidine compounds YUHAN CORPORATION (KR) 2023-05-23 US disclosed
CN-108430972-B Alpha, beta-unsaturated amide compound 协和麒麟株式会社 2022-12-27 CN disclosed
US-11447471-B2 α,β-unsaturated amide compound KYOWA KIRIN CO., LTD. (JP) 2022-09-20 US disclosed
EP-4055014-A1 PYRROLIDINE AND PIPERIDINE COMPOUNDS Yuhan Corporation (KR) 2022-09-14 EP disclosed
CN-114867719-A Pyrrolidine and piperidine compounds 柳韩洋行 2022-08-05 CN disclosed
US-8853203-B2 Diazepinone derivatives NOVARTIS AG (CH) 2014-10-07 US disclosed
WO-2014030128-A1 DIAZEPINONE DERIVATIVES USEFUL FOR THE TREATMENT OF FRAGILE X SYNDROME, PARKINSONS OR REFLUX DISEASE NOVARTIS AG (CH) 2014-02-27 WO disclosed
US-20140057902-A1 Diazepinone derivatives NOVARTIS AG (CH) 2014-02-27 US disclosed
US-8450363-B2 Inhibitors of Jun N-terminal kinase ELAN PHARMACEUTICALS, INC. (US) 2013-05-28 US disclosed
US-20130072494-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. 2013-03-21 US disclosed
EP-2393806-A1 INHIBITORS OF JUN N-TERMINAL KINASE Elan Pharmaceuticals Inc. (US) 2011-12-14 EP disclosed
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase ELAN PHARMACETICALS, INC. 2010-12-30 US disclosed
WO-2010091310-A1 INHIBITORS OF JUN N-TERMINAL KINASE ELAN PHARMACEUTICALS, INC. (US) 2010-08-12 WO disclosed
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 PCSK9, PCSK6, PCSK7 AXL 4396/4885MEN1 1103/4885KMT2A 3815/4885
US-11447471-B2 α,β-unsaturated amide compound NR1H2, RXRA, RXRB AXL 1237/4885MEN1 1979/4885KMT2A 927/4885
US-20130072494-A1 INHIBITORS OF JUN N-TERMINAL KINASE CHUK, MAPK6, MAPK3 AXL 4078/4885MEN1 4655/4885KMT2A 1549/4885
US-20140057902-A1 Diazepinone derivatives ADRB1, ADRB2, BRD4 AXL 4561/4885MEN1 283/4885KMT2A 1088/4885
US-11655235-B2 Pyrrolidine and piperidine compounds FAP, APC, VHL AXL 3917/4885MEN1 2004/4885KMT2A 2822/4885
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 AXL 708/4885MEN1 2238/4885KMT2A 1376/4885
US-20100331335-A1 Inhibitors of Jun N-Terminal Kinase CHUK, MAPK6, MAPK3 AXL 4078/4885MEN1 4655/4885KMT2A 1549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.